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Abstract
Background: The approved immunomodulatory agents for the treatment of multiple sclerosis (MS) are only partially
effective. It is thought that the combination of immunomodulatory and neuroprotective strategies is necessary to prevent
or reverse disease progression. Irradiation with far red/near infrared light, termed photobiomodulation, is a therapeutic
approach for inflammatory and neurodegenerative diseases. Data suggests that near-infrared light functions through
neuroprotective and anti-inflammatory mechanisms. We sought to investigate the clinical effect of photobiomodulation in
the Experimental Autoimmune Encephalomyelitis (EAE) model of multiple sclerosis.
Methodology/Principal Findings: The clinical effect of photobiomodulation induced by 670 nm light was investigated in
the C57BL/6 mouse model of EAE. Disease was induced with myelin oligodendrocyte glycoprotein (MOG) according to
standard laboratory protocol. Mice received 670 nm light or no light treatment (sham) administered as suppression and
treatment protocols. 670 nm light reduced disease severity with both protocols compared to sham treated mice. Disease
amelioration was associated with down-regulation of proinflammatory cytokines (interferon-c, tumor necrosis factor-a) and
up-regulation of anti-inflammatory cytokines (IL-4, IL-10) in vitro and in vivo.
Conclusion/Significance: These studies document the therapeutic potential of photobiomodulation with 670 nm light in
the EAE model, in part through modulation of the immune response.
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Introduction
Multiple sclerosis (MS) is a chronic neurodegenerative disease
characterized by demyelination, axonal degeneration and subse-
quent loss of motor function. MS is considered autoimmune in
nature, mediated by myelin-reactive CD4
+ T cells. Recent studies
suggest mitochondrial dysfunction and oxidative stress contribute
to chronic MS [1–3]. Currently approved therapies, including the
b-Interferons, Copaxone, and monoclonal antibody therapies,
target the immune response and are only partially effective [4–7].
Until therapeutic strategies addressing the ongoing demyelination
and axonal damage are developed, treatment of MS will remain
incomplete.
Experimental Autoimmune Encephalomyelitis (EAE) is a well-
studied, CD4
+ T-cell-mediated inflammatory demyelinating
disease of the central nervous system (CNS) and serves as the
primary animal model for MS [8]. Much of what is understood of
the pathogenesis of MS, as well as many therapeutic advances are
derived from studies using the EAE model. It is generally accepted
that autoreactive, myelin-specific T cells are responsible for disease
initiation. However, as has been noted in MS, recent studies
suggest that oxidative/nitrosative stress play a key role in the
pathogenesis of EAE. Studies by Qi et al. demonstrated
nitrosylation of CNS proteins very early in the disease process,
prior to any evidence of immune infiltration, and prevention of
nitrosoxidative stress ameliorated clinical EAE [9,10]. Studies by
Dutta et al support a central role for oxidative/nitrosative stress in
the axonal loss leading to permanent disability [2,3].
Photobiomodulation (PBM) employing light in the far-red (FR)
to near-infrared (NIR) range (630–1000 nm) with low-energy
lasers or light-emitting diode (LED) arrays has shown a therapeutic
effect in various clinical conditions. Far-red/near-infrared light has
been used clinically for 30 years for the treatment of soft tissue
injuries and to promote wound healing [11–13]. More recent
studies have demonstrated the therapeutic potential of photo-
biomodulation with FR/NIR light in the treatment of chemo-
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30655therapy or radiation-induced mucositis in bone marrow transplant
patients [14], ischemic injury in the heart [15–17], and
neurodegenerative diseases [18–23]. The therapeutic mechanism
of photobiomodulation is believed to function through activation
of cellular photoacceptors and subsequent activation of transcrip-
tion factors leading to improved energy metabolism and
mitochondrial function [24–26]. As MS pathogenesis is due to
an interaction of chronic inflammatory processes and mitochon-
drial dysfunction, we hypothesized that FR/NIR light therapy
would ameliorate disease pathogenesis in MOG35–55 peptide-
induced EAE in C57BL/6 (B6) mice.
Previous studies indicate that the photoacceptor through which
FR/NIR light mediates the observed effects is cytochrome C
oxidase, a key molecule in the electron transport chain leading to
production of ATP [26–28]. The action spectrum of FR/NIR
light overlays the absorption spectrum of cytochrome C oxidase:
the biological activity of FR/NIR light is most pronounced around
670 nm and 830 nm with a nadir in both spectra around 728 nm,
mirroring the absorption spectrum of cytochrome C oxidase [26].
Based on previous studies characterizing the action spectrum of
FR/NIR light and the absorption spectrum of cytochrome c
oxidase, we investigated therapeutic potential of photobiomodula-
tion by 670 nm light for the treatment of MS using the EAE
model. Treatment with 670 nm light prior to or with the onset of
clinical signs resulted in amelioration of clinical EAE. Subsequent
studies revealed decreased expression of proinflammatory cyto-
kines and increased expression of anti-inflammatory cytokines by
lymph node cells exposed to 670 nm light compared to sham
treatment. Similar results were observed in spinal cords isolated
from mice over the course of EAE. Hence, our findings support
the hypothesis that photobiomodulation induced by 670 nm light
ameliorates disease severity in EAE.
Results
Treatment with 670 nm Light Modulates Cytokine
Production by Lymph Node Cells
Previous studies demonstrated up-regulation of anti-inflamma-
tory cytokines and down-regulation of inflammatory cytokines by
FR/NIR light in animal models of acute and chronic inflamma-
tion [29,30]. To determine if a similar effect is evident in antigen-
specific immune responses, the direct effect of 670 nm light on
cytokine production by antigen-primed immune cells was
investigated. Peripheral lymph node cells isolated from MOG35–
55-immunized mice were cultured with cognate peptide and
received once daily treatment with 670 nm light or no light
treatment for 96 h, and cytokine production was analyzed in
supernatants. An antigen-specific effect of 670 nm light on
cytokine production was noted, with down-regulation of IFN-c,
but up-regulation of IL-10 protein expression compared to cells
not exposed to light treatment (Figure 1A, P,0.0001 and
Figure 1B, P,0.0001). Stimulation of lymph node cells with the
mitogenic lectin, Concanavalin A (ConA), resulted in cytokine
expression similar to that observed by sham treated cells (Figure 1).
A small but significant increase in IFN-c was noted by ConA-
stimulated lymph node cells treated with 670 nm light vs. sham
treated cells at 96 h (Figure 1C). No significant difference in IL-10
expression by ConA stimulated cells was noted between treatment
groups (Figure 1D).
Amelioration of Clinical EAE by Treatment with 670 nm
Light
The immune modulation by 670 nm light observed in vitro
would be expected to result in clinical improvement of EAE. The
therapeutic potential of 670 nm light in the treatment of EAE/MS
was initially investigated with a suppression protocol. Following
immunization with MOG35–55, mice received 670 nm630 nm
light emitted by an LED array (75 cm
2) at a fluence of 5 J/cm
2 at
the dorsal surface of the mouse beginning the day after
immunization and continuing for 10 days. Disease was compared
to sham treated animals subjected to restraint stress only. Animals
receiving 670 nm light treatment presented with clinically less
severe disease compared to animals exposed to restraint stress only
(Figure 2A, B; P,0.0001 by 2-way ANOVA; Area Under the
Curve (AUC) P,0.001 by 1-way ANOVA). The beneficial effect
of 670 nm light was evident as a more sustained recovery in
670 nm treated animals compared to restraint stress-treated group
(Figure 2C; P,0.01). This effect was temporary, as treated animals
did eventually relapse to similar disease severity as sham treated
animals (Figure 2A).
To address whether established disease could be ameliorated
after the onset of clinical signs, 670 nm light therapy was initiated
on the day of disease onset. Initial studies demonstrated a similar
effect on disease course as was noted with the suppression protocol
when animals received 670 nm light for 7 days beginning the day
of disease onset (‘‘Onset Protocol’’), including eventual relapse to
similar disease severity (not shown). In an attempt to improve the
clinical efficacy of photobiomodulation by 670 nm light, the
‘‘Double-treatment Protocol’’ was developed. Treatment was
initiated on the day of onset and continued for 7 days. This was
followed by a 7 day ‘‘rest’’ period when animals received no light
treatment and a subsequent 7 day treatment period. Comparison
of disease severity in 670 nm light treated animals vs. those treated
with restraint stress only revealed an improved clinical effect with
this modified treatment protocol (Figure 2D; P,0.0001 by 2-way
ANOVA; Figure 2E: AUC: P=0.0003 by 1-way ANOVA).
Furthermore, the observed treatment of 670 nm light was
sustained throughout the duration of the experiment. Thus,
photobiomodulation with 670 nm light showed a beneficial effect
on the clinical course of actively induced EAE.
Treatment with 670 nm Light Modulates Cytokine
Production Over the Course of EAE
In vitro studies suggested that 670 nm light modulates antigen-
specific cytokine production, shifting the balance of proinflamma-
tory and anti-inflammatory cytokines in a manner that would be
beneficial to the clinical course of EAE. To determine if a similar
cytokine shift could be detected in treated mice over the course of
EAE, gene expression was assayed by QPCR of cDNA from
peripheral lymph nodes (PLN) and spinal cords (SC) isolated over
the course of EAE from mice treated with 670 nm light or restraint
stress by the suppression protocol. Similar to the in vitro
observations, IFN-c (Figure 3A) and TNF-a (Figure 3B) expression
was significantly down-regulated in SC of EAE mice treated with
670 nm light compared with restraint-only treated animals. A
concomitant up-regulation in IL-4 and IL-10 was noted in the
spinal cord over the course of EAE (Figure 3C, D). Similar shifts in
cytokine expression in the PLN at peak disease were also observed
(data not shown).
To determine whether similar cytokine modulation could be
detected with the treatment of established disease, cytokine
expression within the PLN and SC over the course of disease
from animals treated with the double-treatment protocol was
analyzed (Figure 4). A non-significant decrease in proinflamma-
tory cytokine gene expression was noted in both PLN (data not
shown) and SC (Figure 4A, B). However, increased anti-
inflammatory cytokine expression was noted at both sites, with
significant up-regulation of IL-4 at peak of acute disease (Figure 4C
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chronic disease (Figure 4D and data not shown).
Discussion
Multiple Sclerosis (MS) is a leading cause of neurologic disability
in young adults. Disease pathogenesis is complex. Based on studies
in the EAE model, disease is believed to be initiated by
autoreactive CD4+ Th1 and/or Th17 lymphocytes specific for
myelin proteins [31]. These cells are activated in the periphery by
unknown mechanisms and infiltrate the CNS where they secrete
proinflammatory cytokines (e.g., IFN-c, TNF-a, IL-17) to initiate
and propagate a proinflammatory response leading to demyelin-
ation of CNS axons by multiple mechanisms, including: cytokine-
mediated demyelination by TNFa [32]; antibody-mediated
mechanisms, 6 complement [33–35]; macrophage/phagocytic
mechanisms [36–38]; and oxidative stress [2,3]. Ongoing insult
leads to axonal loss and permanent disability [3,39]. More recent
studies indicate that disease progression is due to non-immune
mechanism, suggesting a role for oxidative stress in the axonal loss
occurring late in the disease process [2,3].
The FDA-approved therapeutics for MS act through immuno-
suppressive or immunomodulatory mechanisms, targeting those
processes important to the initiation of clinical activity associated
with the relapsing/remitting phase of disease [4–6,40–42]. These
agents slow disease progression but do not prevent it, and are
ineffective in secondary progressive or primary progressive disease,
perhaps because they fail to provide a neuroprotective component.
Thus, the development of new agents or adjunct therapies
preventing demyelination or axonal loss, or promoting remyelina-
tion and oligodendrocyte function, is of great interest.
The therapeutic application of light to elicit a biological
response has been studied using different modalities and different
wavelengths. Various approaches, all involving introduction of an
exogenous photosensitizer which is then activated to elicit a
clinical effect, have been employed in a variety of systems,
including the EAE model [43–47]. The biological response of
ultraviolet light is well recognized [48–53], and has been studied in
the EAE model [54]. Photobiomodulation, also referred to as Low
Level Light Therapy (LLLT), as employed in the current studies,
differs from these previous modalities in the use of FR/NIR light
delivered in the absence of an exogenous photosensitive moiety
(reviewed in [25]). Photobiomodulation has recently attracted
increased attention. In particular, photobiomodulation performed
with FR/NIR light has demonstrated efficacy in chronic wound
healing in clinical and experimental systems [12,13,30] and for the
treatment of neurodegenerative diseases [18–20,22], including
Parkinson’s disease [22,23,55], retinitis pigmentosa [20], and
stroke [56,57]. As MS pathogenesis is proinflammatory and
neurodegenerative, we investigated the therapeutic potential of
FR/NIR light using the EAE model.
Figure 1. 670 nm light modulates in vitro cytokine production by lymph node cells. Draining peripheral lymph nodes (PLN) were isolated
at 10 days post immunization (dpi) from mice immunized with MOG35–55. Single cell suspensions were cultured (A,B) in the presence or absence of
MOG35–55 or (C,D) with ConA (1 mg/mL) and were treated with 670 nm light (open symbols) or received no light treatment (closed symbols) once
daily for 96 h. Cytokine ELISA was performed on supernatants for (A,C) IFN-c and (B,D) IL-10. Data reported as background-subtracted (e.g., in the
absence of MOG35–55 peptide) antigen-specific cytokine secretion. Data representative of 3 separate experiments. Error bars: SD. P,0.0001 by 2-way
ANOVA. Multiple comparisons made via Bonferroni posttest; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0030655.g001
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lightled to amelioration of theclinicalseverityofMOG35–55 induced
EAE compared to sham-treated animals when treatment was
initiated following immunization but prior to onset of clinical signs
(e.g., suppression protocol) and by a single 7 day treatment protocol
initiated on the day of disease onset (e.g., treatment protocol).
Interestingly, the effect noted with these 2 protocols (e.g., decreased
severity of the acute phase and increased duration of recovery) was
similar. Furthermore, no effect on the onset of clinical signs was
noted with the suppression protocol. These data suggest that there is
noeffectontheinductionoftheautoimmuneresponse,butratheron
the pathogenic mechanisms affecting the disease process.
Figure 2. 670 nm light treatment reduces mean clinical score and signs of MOG-induced EAE. EAE was induced with MOG35–55, and mice
were treated with 670 nm light or no light (restraint) stress [sham]. (A) Mice treated with the suppression protocol. 670 nm light (-%-; n=8) or sham
(-&-; n=9). Representative 3 separate experiments with total n=36 (670 nm light); n=37 (sham). Error bars represent SEM. P,0.0001 by 2-way
ANOVA. (B) Clinical course was plotted and the area under the curve (AUC) for all mice treated with the suppression protocol was determined and
compared by 1-way ANOVA. Horizontal line: median value; Error bars: SEM. P,0.001. (C) duration of recovery for all mice treated with the
suppression protocol was determined by counting the days of recovery from peak disease (decrease in 1 disease score) to the time of relapse
(increase of 1 disease score); horizontal line: median value. (D) Mice were treated with 670 nm light (-%-; n=10) or no light (restraint stress; -&-;
n=7) using the double-treatment protocol. Representative of 3 separate experiments with a total n=24 (670 nm) or 2 separate experiments n=14
(restraint only-sham). Error bars represent SEM. P,0.0001 by 2-way ANOVA. (E) The AUC of clinical disease curves for all mice treated with the double
treatment was determined; horizontal line: median value. Error bars: SEM; P=0.0003 by 1-Way ANOVA. **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0030655.g002
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when a second treatment period was added (e.g., double-treatment
protocol), leading to sustained clinical improvement in affected
animals. The improved efficacy of the double-treatment protocol is
explained by the current understanding of disease pathogenesis
and the therapeutic mechanism of photobiomodulation. MS and
EAE are, by nature, relapsing-remitting diseases, with initial
attacks due to immunoregulatory mechanisms. While the B6
model of EAE employed here displays a more chronic phenotype,
mice do often times recover partially from peak disease scores
attained during the acute phase. Disease progression or sustained
neurological deficit is thought to be due to oxidative damage to
CNS axons. Photobiomodulation mediated by FR/NIR light is
hypothesized to induce gene transcription, mediated by interaction
of FR/NIR light with the cytochrome c oxidase photoacceptor
[26]. Cytochrome c oxidase is an important participant in the
electron transport chain, critical for the maintenance of mito-
chondrial function. The molecule binds, interchangeably, molec-
ular oxygen and nitric oxide. Nitric oxide is known to mediate
intracellular signal transduction cascades and communication
between the mitochondrion and the nucleus [58]. Thus,
interaction of FR/NIR light with cytochrome c oxidase is thought
to lead to the release of nitric oxide, initiating signaling
transduction cascades culminating in activation of transcription
and translation of nuclear-encoded proteins, leading to the
observed effects of photobiomodulation [17,59–61]. A recent
study by Chen et al suggests that the observed effects are at least in
part mediated by the transcription factor, NFkB, and an increase
in cellular ATP synthesis [62]. In the EAE model, these effects are
apparent as down-regulation of pro-inflammatory mechanisms
and up-regulation of anti-inflammatory mechanisms. Thus, gene
induction by suppression and treatment protocols would be
expected to be similar. However, with the cessation of the
suppression protocol at or around the day of onset, gene
transcription would eventually return to pre-treatment levels, thus
abrogating the protective effect of FR/NIR light. On the other
hand, the double-treatment protocol would be expected to sustain
gene transcription and improve the clinical effect.
The structure of the double treatment protocol, with inclusion
of a 7 day rest period, was developed with insight provided by
other protocols not presented here. For example, early studies
employed a protocol in which treatment was initiated the day after
immunization and continued through the peak of disease. This
protocol resulted in a worsening of clinical signs in 670 nm-treated
animals compared to sham-treated mice. This could be due to the
dual role of iNOS/nitric oxide in regulation of EAE and the
immune response [63–68]. These studies indicated that nitric
oxide is important in regulating T cell activation to neuroantigens
during disease initiation [63] while playing a pathogenic role in
ongoing disease [2,64]. The 7 day rest period typically occurs
during the remission/recovery phase of disease when the immune
response responsible for relapse is being primed, and treatment is
Figure 3. The suppression treatment protocol results in cytokine modulation within the CNS over the course of EAE. Spinal cords (SC)
were isolated from MOG35–55-immunized mice treated with the suppression protocol and QPCR was performed to quantify cytokine gene expression.
Relative gene expression was determined by the Paffl method (2000) Gene expression was normalized at each disease stage with sham treated mice.
(A) INF-c;( B) TNF-a;( C) IL-4; (D) IL-10. n=4 mice per group. Error bars indicated SD between 2 independent experiments. Data analyzed 2-way
ANOVA. Multiple comparisons by Bonferroni post-test. *P,0.05, **P,0.01, ***P,0.0001, n.s=not significant.
doi:10.1371/journal.pone.0030655.g003
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relapse. Thus, this 7 day rest period may be providing an
opportunity for important immunomodulatory functions of nitric
oxide to occur, preventing excessive activation of autoreactive T
cells, while subsequent treatment is down-regulating the patho-
genic contribution of nitric oxide to disease progression. In support
of this, more recent studies incorporating a third treatment period
following a second 7 day rest demonstrated continued suppression
of clinical signs in treated animals.
In vitro and in vivo experiments demonstrate modulation of pro-
inflammatory vs. anti-inflammatory cytokines by 670 nm light in a
manner consistent with the observed effects on disease course. It is
interesting to note that immunomodulation appears to require
signaling through antigen-specific mechanisms (i.e., the T cell
receptor; TcR), as evidenced by a lack of cytokine modulation
when cells are stimulated with ConA. ConA is a mitogenic lectin
that activates T cells in a polyclonal manner via cross-linking of
cell-surface b-glycans. It is generally used as a positive control for
cell viability and the ability to respond to appropriate stimulatory
signals. It does not interact with nor signal through the antigen-
specific TcR and therefore activates different signal transduction
cascades than would antigen-specific activation through the TcR
and requisite co-stimulatory pathways (e.g., CD28). This observa-
tion could not only have relevance to the clinical application of
670 nm-mediated photobiomodulation but could also provide
insight into the mechanisms behind the observed clinical effects.
The neuroprotection afforded by FR/NIR light noted in other
systems is thought to be due to down-regulation of oxidative stress
and improved cytoprotective mechanisms [25,59,69]. Indeed,
ongoing studies suggest that similar mechanisms are involved in
the observed effect of 670 nm light on the EAE disease course.
However, given the autoimmune nature of MS and the described
complications associated with monoclonal antibody therapies [70],
as well as the known effects on chronic inflammation, it is
important to understand the effect of FR/NIR light on the
immune response. Understanding of the effect of FR/NIR light on
immunity is limited [30,71,72]. Data from in vitro and ex vivo studies
presented here demonstrate an immunomodulatory effect of
670 nm light on antigen-specific cytokine production, with
down-regulation of proinflammatory cytokines, IFN-c and TNF-
a, and up-regulation of anti-inflammatory cytokines, IL-4 and IL-
10. These cytokine changes would be expected to have a beneficial
effect in the EAE model and on the clinical course of MS
[4,31,73,74].
Ongoing studies seek to develop photobiomodulation as an
adjunct therapy for the treatment of MS, used in conjunction with
the currently approved immunomodulatory agents. However,
several questions need to be answered before translation into
human system will be possible, including optimization of treatment
wavelength, the nature of the treatment device, and the
penetration of light to affected structures. A recent comprehensive
review indicates photobiomodulation may achieve different
Figure 4. The Double-Treatment protocol results in up-regulation of anti-inflammatory cytokines within the CNS over the course of
EAE. Spinal cords (SC) were isolated from MOG35–55-immunized mice treated with the double-treatment protocol and QPCR was performed to
quantify cytokine gene expression. Gene expression was normalized at each disease stage with sham treated mice. (A) INF-c;( B) TNF-a;( C) IL-4; (D)
IL-10. n=4 mice per group. Error bars indicate SD between 2 independent experiments. Data were analyzed by 2-way ANOVA. Multiple comparisons
by Bonferroni post-test. *P,0.05, **P,0.01, ***P,0.0001, n.s.=not significant.
doi:10.1371/journal.pone.0030655.g004
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on choice of photobiomodulation parameters. These parameters
include; 1) the optical properties of tissues, and 2) dositometry (i.e
irradiance and dosing) [60]. A primary question that needs to be
addressed before these questions can be answered is whether the
observed effects are due to systemic effects or targeted (e.g., within
the CNS) effects of light on the system. The total body irradiation
employed here leaves this up to debate. The total body irradiation
used here could result in systemic, transcutaneous effects as well as
effects mediated by transmission of light through the optic nerve.
On the one hand, the immunomodulation noted in the current
studies may support a systemic effect, or at least an effect in the
periphery as opposed to the CNS, as the disease-inducing T-cells
must be activated in the periphery in order to traverse the blood
brain barrier and cause disease [75,76]. In addition, the
immunomodulatory effects noted in the suppression protocol
would have been primed in the lymph nodes. On the other hand,
light would also be transmitted via the optic nerve or could directly
penetrate the spinal cord. Ongoing studies demonstrate decreased
oxidative stress and apoptosis within the spinal cord of treated
animals. Furthermore, recent studies utilizing a similar LED
device demonstrated that transmission of light via the optic nerve
preserved CNS function following transection of the optic nerve
[77]. These will be challenging questions to answer, and it is
possible that both systemic and targeted mechanisms contribute to
the observed clinical effects. Further studies and procurement of
additional instrumentation will be necessary to address these
questions, and the answers to these questions will be important to
the translation of these studies to the human population.
Several studies have established the role of immune system in
EAE and MS [31]. Recent studies have implicated other
pathogenic mechanisms, including mitochondrial dysfunction
and oxidative/nitrosative stress in EAE and MS [2,3,9,10,62].
Data presented here show that treatment with 670 nm light
ameliorates disease severity in EAE, in part through immuno-
modulatory mechanisms. Ongoing studies further investigate the
observed immune modulation and address the role of FR/NIR
light in preservation of mitochondrial function and remediation of
oxidative stress in the EAE model. These experiments suggest a
combination of both mechanisms in the amelioration of EAE,
indicating that photobiomodulation may be valuable as an adjunct
therapy for the treatment of MS.
Materials and Methods
Animals
Specific pathogen-free female C57BL/6 (B6) WT mice were
bred in-house from breeding pairs purchased from Jackson
Laboratories (Bar Harbor, ME). Mice were maintained in
micro-isolator cages in an AAALAC-accredited facility in
accordance with University and NIH guidelines. All animals were
supplied with food and water ad libitum and maintained on a 12 h
light/dark schedule in a temperature and humidity-controlled
environment.
Antigens and EAE induction
The mouse MOG35–55 peptide (MEVGWYRSPFSRVVH-
LYRNGK) was synthesized and purity confirmed by HPLC
(GenScript, Piscataway, NJ). EAE was induced in mature mice (6–
8 weeks old) by immunization with 100 mg MOG35–55 peptide
emulsified (1:1) in IFA with 300 mg Mycobacterium tuberculosis, strain
H37RA (Bectin Dickinson, FranklinLakes, NJ). Each mouse
received 0.05 mL emulsion (s.c.) at four sites. In addition, animals
received pertussis toxin (300 ng i.p.; List Laboratories, Campbell,
CA) at 0 h and 72 h post immunization. Animals were followed
for the development of EAE and graded clinically on a scale of 0–5
by a blinded observer [0: healthy, no signs of EAE; 1: loss of tail
tone; 2: hind limb weakness; 3: paresis or paralysis of one hind
limb; 4: paralysis of both hind limbs; 5: dead or moribund].
LED Treatment
Gallium/Aluminum/Arsenide (GaAlA) LED arrays (75 cm
2)o f
670 nm (LED bandwidth 25–30 nm at Full Width Max Power
[FWHM]) were obtained from Quantum Devices (Barneveld, WI).
Unanesthetized Mice were placed individually into a polypropyl-
ene restraint device (12.76967.6 cm), and the LED array was
positioned directly over the animal at a distance of 2 cm, covering
the entire chamber and exposing the entire dorsal surface.
Treatment consisted of once daily irradiation at 670 nm for
3 min, at a power intensity of 28 mW/cm
2 (total power output:
2100 mW) and an energy density of 5 J/cm
2 (375 J daily total). To
determine the energy density at the level of the spinal cord, a small
incision was made at the base of the tail, and a probe was inserted
underneath the skin at the base of the brain, demonstrating an
energy density of 12 mJ/cm
2 (432 mJ total energy administered
daily) at the level of the spinal cord. As indicated, ‘‘restraint only’’
stress was employed, in which mice were placed in the restraint
device for 3 min but not exposed to light. The Suppression
Protocol consisted of once daily treatment for 10 consecutive days
starting 24 h post immunization, resulting in a total of 4320 J at
the level of the spinal cord administered to the animal over the
course of treatment. Treatment protocols were performed as the
‘‘Onset Protocol’’, consisting of once daily treatment for 7
consecutive days beginning the day of onset of clinical signs
(clinical score=1.0; 3024 J total energy administered), and the
‘‘Double Treatment Protocol’’, consisting of once daily treatments
initiated on the day of onset of clinical signs for 7 days, followed by
7 days rest, and a subsequent 7 day treatment period (6048 J total
energy administered). Clinical disease was followed for an
additional 7 days following cessation of the second treatment
period.
Real-time PCR
Mice were anesthetized with ketamine cocktail and perfused
with 60 mL cold PBS via cardiac puncture. Total RNA was
isolated from the spinal cord (SC) and the draining peripheral
lymph nodes (PLN; e.g., popliteal, brachial and axillary lymph
nodes.) using the Trizol method according to manufacturer’s
instructions (Invitrogen, Carlsbad, CA). RNA was further purified
utilizing the RNEasy kit, with genomic DNA elimination columns
and subsequent on-column DNase treatment to eliminate genomic
DNA contamination (Qiagen, Valencia, CA). RNA (2 mg) was
reverse transcribed using oligo dT primer (Operon, Huntsville,
AL) and MMLV reverse transcriptase (Promega, Madison, WI)
according to the manufacturer’s instructions. Probe-based quan-
titative real-time PCR (QPCR) was performed for IFN-c, TNF-a,
IL-10, IL-4. b-actin was included as the housekeeping gene, and
water blanks were included in all experiments. Primer/Probe sets
were designed using the Universal Probe Design software (Roche
Applied Science, Indianapolis, IN). Primers were designed to span
introns, when possible. Primers were purchased from Sigma (St.
Louis, MO), and probes were purchased from Roche Applied
Science. Amplifications were performed using TaqManHUniversal
PCR Master Mix (Roche Applied Science) on a SmartCycler
(Cepheid, Sunnyvale, California), programmed for 95uC for
10 min, followed by 40 cycles of 95uC for 15 s and 60uC for
1 min, with detection of signal during the annealing/amplification
segment. Results were calculated via the Pfaffl method (Pfaffl 2001)
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to gene expression in samples isolated from sham treated animals
at the same disease stage.
Cytokine ELISA
Draining PLN were pooled from 6 mice 10 days post
immunization (dpi) with 100 mg MOG35–55. Single cell suspen-
sions were prepared, and cells (2.5610
6/mL) were cultured in
supplemented RPMI 1640 [10% FCS, penicillin (100 U/mL)/
streptomycin (100 mg/mL), L-glutamate (2 mM), Sodium pyru-
vate (0.1 mM), 2-mecarptoethanol (50 mM)] in 96-well flat-
bottom plates (BD Biosciences, San Jose, California, USA) in the
presence or absence of 10 mg/mL MOG35–55 peptide. Stimulation
of cells with concanavalin A (ConA; 1 mg/mL) served as a positive
control for cell viability. Cell cultures were treated once daily with
670 nm light or no light treatment beginning 2 h after plating and
continuing at 24 h intervals for 96 h. Cell culture supernatants
were isolated at 48 h, 72 h, 96 h, and 120 h and analyzed for
IFNc (,2.0 pg/mL detection limit) and IL-10 (,4.0 pg/mL
detection limit) utilizing Quantikine kits according to manufac-
turer’s instructions (R&D Systems, Minneapolis, MN). Data is
reported as background-corrected (e.g., in the absence of peptide),
antigen-specific cytokine secretion.
Data Analysis
Data were analyzed and statistical analyses were performed
using GraphPad Prism 4.0 (GraphPad, La Jolla, CA USA).
Clinical course was compared by 2-way ANOVA. AUC analysis
was compared by 1-way ANOVA (Kruskal-Wallis test); multiple
comparisons performed by Dunn’s Multiple Comparisons test or
Bonferroni correction, as indicated. Mann-Whitney U-test and
Student’s t-test performed, as appropriate. P,0.05 was considered
significant.
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